Amgen’s experimental obesity drug, MariTide, led to an average 20% reduction in weight in a Phase 2 clinical trial. While investors hoped for greater weight loss, some analysts say less burdensome monthly dosing of MariTide could make it competitive against weekly injectable weight drugs Zepbound and Wegovy.
The post Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator appeared first on MedCity News.
